Know Cancer

or
forgot password

10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors


N/A
50 Years
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors


Inclusion Criteria:



- Early Breast Cancer patients

- Postmenopausal Status

- patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months

Exclusion Criteria:

- Advanced Breast Cancer patients(stage iii, iv)

- Patients who are hard to be analysed by limitation of chart record according to
investigators discretion

- patients who already have been registered in this study

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Outcome Measure:

The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment.

Outcome Time Frame:

1 visit

Safety Issue:

No

Principal Investigator

JoonWoo Bahn, MD, PhD

Investigator Role:

Study Director

Investigator Affiliation:

AstraZeneca Korea

Authority:

Korea: Food and Drug Administration

Study ID:

NIS-OKR-DUM-2009/1

NCT ID:

NCT00885612

Start Date:

May 2009

Completion Date:

March 2010

Related Keywords:

  • Breast Cancer
  • CHD-Risk
  • Breast Cancer
  • Aromatase Inhibitors
  • postmenopausal early breast cancer
  • Breast Neoplasms
  • Coronary Disease

Name

Location